[HTML][HTML] Performance of a cooperative multiplexing scheme with opportunistic user and relay selection over Rayleigh fading channels

DK Verma, S Prakriya - EURASIP Journal on Wireless Communications …, 2012 - Springer
In this article, we analyze the performance of a cooperative spatial multiplexing scheme
using amplify and forward relays over Rayleigh fading channels. We propose a simple user …

[HTML][HTML] Genophenotypic factors and pharmacogenomics in adverse drug reactions

R Cacabelos, V Naidoo, L Corzo, N Cacabelos… - International journal of …, 2021 - mdpi.com
Adverse drug reactions (ADRs) rank as one of the top 10 leading causes of death and
illness in developed countries. ADRs show differential features depending upon genotype …

[HTML][HTML] Current methodological issues in the economic assessment of personalized medicine

L Annemans, K Redekop, K Payne - Value in Health, 2013 - Elsevier
There is a need for methodological scrutiny in the economic assessment of personalized
medicine. In this article, we present a list of 10 specific issues that we argue pose specific …

[HTML][HTML] How is genetic testing evaluated? A systematic review of the literature

E Pitini, C De Vito, C Marzuillo, E D'Andrea… - European Journal of …, 2018 - nature.com
Given the rapid development of genetic tests, an assessment of their benefits, risks, and
limitations is crucial for public health practice. We performed a systematic review aimed at …

[HTML][HTML] Breast cancer MCF-7 cell spheroid culture for drug discovery and development

G Chen, W Liu, B Yan - Journal of cancer therapy, 2022 - ncbi.nlm.nih.gov
In vitro 3D cancer spheroids (tumoroids) exhibit a drug resistance profile similar to that found
in solid tumors. 3D spheroid culture methods recreate more physiologically relevant …

Economic evaluations of personalized medicine: existing challenges and current developments

FH Shabaruddin, ND Fleeman… - Pharmacogenomics and …, 2015 - Taylor & Francis
Personalized medicine, with the aim of safely, effectively, and cost-effectively targeting
treatment to a prespecified patient population, has always been a long-time goal within …

Re: CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women With Endocrine-Responsive Breast Cancer: The Breast International Group 1–98 Trial

V Stanton Jr - Journal of the National Cancer Institute, 2012 - academic.oup.com
References 1. regan mm, Leyland-Jones B, Bouzyk m, et al. CyP2D6 genotype and
tamoxifen response in postmenopausal women with endocrine-responsive breast cancer …

Pharmacogenomics of breast cancer therapy: an update

K Westbrook, V Stearns - Pharmacology & therapeutics, 2013 - Elsevier
Clinical and histopathologic characteristics of breast cancer have long played an important
role in treatment decision-making. Well-recognized prognostic factors include tumor size …

[HTML][HTML] Relationship between Genotypes Sult1a2 and Cyp2d6 and Tamoxifen Metabolism in Breast Cancer Patients

A Fernandez-Santander, M Gaibar, A Novillo… - PloS one, 2013 - journals.plos.org
Tamoxifen is a pro-drug widely used in breast cancer patients to prevent tumor recurrence.
Prior work has revealed a role of cytochrome and sulfotransferase enzymes in tamoxifen …

[HTML][HTML] Adjusting the dose of tamoxifen in patients with early breast cancer and CYP2D6 poor metabolizer phenotype

EM de Dueñas, EO Aranda, IB Lopez-Barajas… - The Breast, 2014 - Elsevier
Background CYP2D6 is a key enzyme in tamoxifen metabolism, transforming it into its main
active metabolite, endoxifen. Poor CYP2D6 metabolizers (PM) have lower endoxifen plasma …